Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asta Baranauskaite

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Annals of the Rheumatic Diseases|May 1, 2016
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyDae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|August 31, 2015
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyJung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, et al.
Arthritis Research & Therapy|January 16, 2009
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA studyTuulikki Sokka, Sergio Toloza, Maurizio Cutolo, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Annals of the Rheumatic Diseases|May 1, 2016
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyDae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|August 31, 2015
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyJung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, et al.
Arthritis Research & Therapy|January 16, 2009
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA studyTuulikki Sokka, Sergio Toloza, Maurizio Cutolo, et al.
Pageof 3